Similar articles

• [Pegylated-interferon-induced diabetes mellitus type 1 in two patients with chronic hepatitis C].

  Primo Vera J. Primo Vera J. Gastroenterol Hepatol. 2004 Feb;27(2):69. doi: 10.1016/s0210-5705(03)79089-x. Gastroenterol Hepatol. 2004. PMID: 14733882 Spanish. No abstract available.
• Retinal vein thrombosis associated with peginterferon alpha 2b plus ribavirin in a chronic hepatitis C patient.

  Such Díaz A, Barrueco N, Esteban Alba C, Escobar Rodríguez I. Such Díaz A, et al. Farm Hosp. 2011 Mar-Apr;35(2):93-4. doi: 10.1016/j.farma.2010.01.010. Epub 2010 Jul 7. Farm Hosp. 2011. PMID: 20615736 English, Spanish. No abstract available.
• Dual onset of type 1 diabetes mellitus and Graves' disease during treatment with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C.

  Hayashi M, Kataoka Y, Tachikawa K, Koguchi H, Tanaka H. Hayashi M, et al. Diabetes Res Clin Pract. 2009 Nov;86(2):e19-21. doi: 10.1016/j.diabres.2009.08.009. Epub 2009 Sep 9. Diabetes Res Clin Pract. 2009. PMID: 19744739
• Peginterferon and ribavirin for chronic hepatitis C.

  Hoofnagle JH, Seeff LB. Hoofnagle JH, et al. N Engl J Med. 2006 Dec 7;355(23):2444-51. doi: 10.1056/NEJMct061675. N Engl J Med. 2006. PMID: 17151366 Review. No abstract available.
• [Side effects of interferon-based therapy for chronic hepatitis C virus infection and clinical management of them].

  Iwasaki Y, Ikeda F, Yamamoto K. Iwasaki Y, et al. Nihon Rinsho. 2011 May;69 Suppl 4:215-20. Nihon Rinsho. 2011. PMID: 22096922 Review. Japanese. No abstract available.